Cargando…
Structural basis of kynurenine 3-monooxygenase inhibition
Inhibition of kynurenine 3-monooxygenase (KMO), an enzyme in the eukaryotic tryptophan catabolic pathway (i.e. kynurenine pathway), leads to amelioration of Huntington’s disease-relevant phenotypes in yeast, fruit fly, and mouse models(1–5), as well as a mouse model of Alzheimer’s disease(3). KMO is...
Autores principales: | Amaral, Marta, Levy, Colin, Heyes, Derren J., Lafite, Pierre, Outeiro, Tiago F., Giorgini, Flaviano, Leys, David, Scrutton, Nigel S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736096/ https://www.ncbi.nlm.nih.gov/pubmed/23575632 http://dx.doi.org/10.1038/nature12039 |
Ejemplares similares
-
Inflammation control and improvement of cognitive function in COVID-19 infections: is there a role for kynurenine 3-monooxygenase inhibition?
por: Collier, Mary EW, et al.
Publicado: (2021) -
A brain-permeable inhibitor of the neurodegenerative disease target kynurenine 3-monooxygenase prevents accumulation of neurotoxic metabolites
por: Zhang, Shaowei, et al.
Publicado: (2019) -
Kynurenine 3-Monooxygenase Interacts with Huntingtin at the Outer Mitochondrial Membrane
por: Swaih, Aisha M., et al.
Publicado: (2022) -
A novel role for kynurenine 3-monooxygenase in mitochondrial dynamics
por: Maddison, Daniel C., et al.
Publicado: (2020) -
Cellular Localization of Kynurenine 3-Monooxygenase in the Brain: Challenging the Dogma
por: Sathyasaikumar, Korrapati V., et al.
Publicado: (2022)